A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
T cell activation requires two signals: TCR engagement with MHC-peptide (signal 1) and costimulation via CD28 binding CD80/CD86 on antigen-presenting cells (signal 2). Signal 1 alone leads to anergy (functional inactivation). Costimulation induces IL-2 production and IL-2 receptor upregulation, driving proliferation and differentiation.
T cell activation is a deliberate two-key security system. A T cell that recognizes antigen through its T cell receptor (TCR) receives what is called signal 1 — confirmation that the right peptide-MHC complex is present. But signal 1 alone is not enough. Without a second, independent signal, the T cell does not activate; instead, it enters a state of anergy, becoming functionally deaf to further stimulation. The reason for this stringency is immunological self-tolerance: self-tissues display peptide-MHC complexes too, and the immune system must not attack them.
Signal 2 is delivered by costimulation: the T cell surface receptor CD28 binds to CD80 or CD86 expressed on the antigen-presenting cell. Critically, CD80/CD86 are not constitutively expressed on every cell — they are upregulated on dendritic cells, macrophages, and B cells in response to infection, inflammation, or Toll-like receptor activation. This means costimulation is a proxy for "a genuine immune threat is present," not just "antigen is present." Self-tissue under normal conditions lacks these ligands, so self-reactive T cells that escape thymic deletion get silenced here instead.
When both signals arrive together, the T cell undergoes a dramatic shift. The transcription factor NFAT is dephosphorylated and enters the nucleus, driving IL-2 gene expression. Simultaneously, the high-affinity IL-2 receptor (which includes the CD25 alpha chain) is upregulated on the cell surface. The T cell thus both produces IL-2 and expresses the receptor to respond to it — a tight autocrine loop that fuels rapid clonal expansion over hours to days.
The downstream consequences of full activation depend on context: CD4+ T cells receiving costimulation in the presence of different cytokines differentiate into distinct helper subsets (Th1, Th2, Th17, Tfh), each specialized for different threats. CD8+ T cells become cytotoxic killers. Without costimulation, none of this differentiation occurs — the two-signal requirement is a filter that gates the entire adaptive immune response.
Understanding this checkpoint has direct therapeutic relevance. Blocking costimulation (e.g., with CTLA-4-Ig, which competes with CD28 for CD80/CD86) suppresses transplant rejection and autoimmunity. Conversely, anti-CTLA-4 antibodies (like ipilimumab) remove an inhibitory signal that mimics the absence of costimulation, reinvigorating exhausted anti-tumor T cells. The two-signal model is not just textbook biology — it is an active target in modern immunotherapy.